FDA Approves Capmatinib for Advanced Lung Cancer

Advanced lung cancer has seen improvements when patients receive therapy targeting abnormalities specific to their tumor. Now, a new FDA approved therapy called capmatinib, is the first therapy available for a group of patients previously ineligible for targeted therapies.